Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2012 | 02:40pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on PFIZER INC
05/25 Sanofi moves to oust Medivation board in $9.3 billion takeover fight
05/25 Sanofi moves to oust Medivation board in $9.3 billion takeover fight
05/24 GLAXOSMITHKLINE : What we must do to avert antibiotic catastrophe
05/24 PFIZER : UN High Commissioner for Human Rights Zeid Ra'ad Al Hussein greets Pfiz..
05/24 PFIZER : Champix label updated to include new safety and efficacy data
05/24DJTax Rule Scuppers $8 Billion Deal -- WSJ
05/23DJCF, OCI Ditch Merger, Citing New U.S. Tax Rules--2nd Update
05/23DJSamsung Targets U.S. Drug Market With Remicade Knockoff
05/23 PFIZER : EU lifts suicide warning on Pfizer's smoking-cessation pill
05/23 Allergan CEO says company is 'weeks away' from closing Teva deal
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials